BlackRock Amends Halozyme Therapeutics Stake, Filing SC 13G/A
Ticker: HALO · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in Halozyme Therapeutics as of year-end 2023.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating its ownership of HALOZYME THERAPEUTICS, INC. common stock as of December 31, 2023. This filing, Amendment No. 3, updates previous disclosures about BlackRock's passive investment in Halozyme. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal confidence or concerns about the company's future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's continued, albeit passively managed, significant stake in Halozyme Therapeutics, which can be a vote of confidence from a major institutional investor.
Risk Assessment
Risk Level: low — This is a routine amendment from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive stake in Halozyme Therapeutics, but this filing alone doesn't suggest a need for immediate action. It's a routine update reflecting institutional ownership.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- HALOZYME THERAPEUTICS, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 3 (number) — the specific amendment number of this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 3)' sections.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What company's securities are the subject of this filing?
The securities of HALOZYME THERAPEUTICS, INC. are the subject of this filing, as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.' and '(Name of Issuer) HALOZYME THERAPEUTICS, INC.'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding HALOZYME THERAPEUTICS, INC. (HALO).